Halozyme Therapeutics, Inc. (BMV:HALO)

Mexico · Delayed Price · Currency is MXN

1,395.66

+14.66 (1.06%)

At close: Feb 6, 2026

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
United States Revenue	-	690.46M	587.20M
United States Revenue Growth	-	17.59%	34.07%
Switzerland Revenue	-	212.39M	149.02M
Switzerland Revenue Growth	-	42.52%	-10.68%
Belgium Revenue	-	84.01M	58.35M
Belgium Revenue Growth	-	43.96%	2694.73%
Japan Revenue	-	18.94M	15.10M
Japan Revenue Growth	-	25.46%	-68.51%
All Other Foreign Countries Revenue (Post-FY2022)	-	9.53M	19.58M
All Other Foreign Countries Revenue (Post-FY2022) Growth	-	-51.35%	272.02%
Revenue (Total)	1.24B	1.02B	829.25M
Revenue (Total) Growth	22.41%	22.44%	25.62%

Revenue

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
Royalties Revenue	780.29M	570.99M	447.87M
Royalties Revenue Growth	36.66%	27.49%	24.24%
Sales of Proprietary Products	182.34M	166.62M	130.83M
Sales of Proprietary Products Growth	9.43%	27.35%	79.60%
Sales of Bulk rHuPH20	102.48M	86.33M	115.44M
Sales of Bulk rHuPH20 Growth	18.70%	-25.21%	40.64%
Sales of Device Partnered Products	48.32M	50.54M	54.58M
Sales of Device Partnered Products Growth	-4.38%	-7.40%	51.20%
Total Net Product Sales	333.14M	303.49M	300.85M
Total Net Product Sales Growth	9.77%	0.88%	57.49%
Revenue Under Collaborative Agreements	129.42M	140.84M	80.53M
Revenue Under Collaborative Agreements Growth	-8.11%	74.88%	-25.85%
Revenue (Total)	1.24B	1.02B	829.25M
Revenue (Total) Growth	22.41%	22.44%	25.62%

Updated Sep 30, 2025. Data Source: Fiscal.ai.